September 2019

On the Horizon - upcoming first generic launches*

TARGET DATE BRAND NAME GENERIC NAME COMMON USE  2018 U.S. BRAND SALES 
4Q2019 OSMOPREP Sodium Phosphate electrolytes Bowel prep for colonoscopy $8M
4Q2019 ACZONE 7.5% Dapsone Acne   $263M
2020 ATRIPLA Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate HIV/AIDS $1,273M
2020 TRUVADA Emtricitabine; Tenofovir Disoproxil Fumarate HIV/AIDS $3,151M
2020 KUVAN Sapropterin Dihydrochloride Phenylketonuria $25M
2020 AFINITOR  Everolimus Kidney cancer $394M
2020 SILENOR Doxepin Hydrochloride Insomnia $47M
2020 CHANTIX Varenicline Tartrate Smoking cessation $702M
2020 ABSORICA Isotretinoin Acne   $308M
2020 CIPRODEX Ciprofloxacin; Dexamethasone Ear Infections $466M
2020 DALIRESP Roflumilast COPD $214M
2020 VELCADE Bortezomib Lymphomas $610M

* Source: IPD Analytics, www.ipdanalytics.com, Accessed August 27, 2019

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require you to use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, contact a Cigna representative. Group medical and pharmacy plans are insured and/or administered by Cigna Health and Life Insurance Company or its affiliates. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. All pictures are used for illustrative purposes only. This website is not intended for residents of New Mexico.

© 2019 Cigna. All rights reserved